Katalyst Diagnostics Ltd

Based in the UK, Katalyst Diagnostics Ltd, operates as a provider of diagnostics solutions and drug monitoring for medical institutions. Based in London, the UK and founded in 2022, Katalyst Diagnostics Ltd provides diagnostic solutions for medical institutions. The company specializes in point-of-care testing and drug monitoring. In September 2026, Katalyst Diagnostics Ltd was acquired by Cruinn Diagnostics Limited, enabling expansion of diagnostics distribution capabilities across Ireland and UK markets.

Katalyst Diagnostics specializes in innovative point-of-care testing (POCT) diagnostic solutions designed to enhance clinical decision-making in various healthcare settings. Their core product offerings include HemoScreen™, MyCare INSITE™, and Piccolo Xpress®, which support NHS and healthcare organizations across the UK and Ireland in emergency departments, oncology, ambulatory care, pediatrics, and mental health pathways. Katalyst Diagnostics utilizes a B2B transaction model, primarily targeting healthcare providers and institutions that require sophisticated diagnostic solutions. The firm engages in direct sales to hospitals and clinics through distributor partnerships and direct contracts, fostering long-term client relationships.

Their flagship products are offered with tailored pricing plans designed to accommodate the varying needs of their clients. The company plans to expand its diagnostics distribution capabilities across Ireland and UK markets following its acquisition by Cruinn Diagnostics Limited.